Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Bovine Colostrum Against Chemotherapy-Induced Gastrointestinal Toxicity in Children With Acute Lymphoblastic Leukemia: A Randomized, Double-Blind, Placebo-Controlled Trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Repeated Metabolic Balance Studies in Patients With Short Bowel Syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Management of Asparaginase Toxicity in AYAs with ALL

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Smartphone App to Self-Monitor Nausea During Pediatric Chemotherapy Treatment: User-Centered Design Process

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Male Sexual Function after Allogeneic Hematopoietic Stem Cell Transplantation in Childhood: A Multicenter Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: The toxic effect of chemotherapy on the gastrointestinal tract may lead to mucositis and is associated with the pathogenesis of other treatment-related complications. We hypothesized that nutrition supplementation with bovine colostrum, rich in bioactive factors, would ameliorate gastrointestinal toxicity and reduce the incidence of fever and infectious complications during induction treatment for childhood acute lymphoblastic leukemia (ALL).

METHODS: Children with newly diagnosed ALL were included in a 2-center, randomized, double-blind, placebo-controlled clinical trial. Patients were randomized to receive a daily colostrum or placebo supplement during 4 weeks of induction treatment. Data on fever, bacteremia, need for antibiotics, and mucosal toxicity were prospectively collected. (Trial registration: www.clinicaltrials.gov NCT01766804).

RESULTS: Sixty-two patients were included. No differences were found for the primary outcome (number of days with fever). No difference was observed for neutropenic fever, intravenous antibiotics, or incidence of bacteremia. Peak severity of oral mucositis was significantly reduced by colostrum (7/29 patients, 24% mild; 6/29, 21% moderate; 1/29, 3% severe) compared with placebo (12/31, 39% mild; 1/31, 3% moderate; 7/31, 23% severe) (P = 0.02). Among patients receiving at least 1 dose of supplement (colostrum: n = 22; placebo: n = 30), the peak weekly self-reported oral mucositis score was overall significantly less severe in the colostrum group (P = 0.009).

CONCLUSION: The use of prophylactic bovine colostrum showed no effect on fever, infectious morbidity, or inflammatory responses. Nevertheless, these data may suggest protective effects on the oral mucosa during induction therapy in childhood ALL, encouraging additional studies confirming these findings.

Original languageEnglish
JournalJournal of Parenteral and Enteral Nutrition
Volume44
Issue number2
Pages (from-to)337-347
Number of pages11
ISSN0148-6071
DOIs
Publication statusPublished - Feb 2020

    Research areas

  • enteral formulas, enteral nutrition, immunonutrition, life cycle, nutrition, oncology, pediatrics, research and diseases

ID: 59083144